Tirzepatide 30mg (10mg/mL + B6 10mg/mL) (3mL Vial)

Name: Tirzepatide 30mg (10mg/mL + B6 10mg/mL) (3mL Vial)*
Brand: BPI LABS
SKU: C22213

Product Details

Manufacturer: BPI LABS

MFG#: C22213

NDC: C22213

PID: 659493

1VL/EA

$ *.**

In Stock

1EA/EA

$ *.**

In Stock

1/EA

$ *.**

In Stock

$ *.**

Add to Cart

Additional Information

Product Name	Tirzepatide 30mg (10mg/mL + B6 10mg/mL) (3mL Vial)
BUD	Assigned per lot on the dispensed label per USP standards and available stability data.
Sterile preparation produced by	BPI Labs (503B outsourcing facility). Registration/listing does not imply FDA approval.
Active Ingredient	Tirzepatide (10 mg/mL), Pyridoxine HCl (B6) (10 mg/mL
Drug Class	GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonist
Mechanism of Action	Activates both the GIP and GLP-1 receptors, which stimulates insulin secretion, inhibits glucagon release, and slows gastric emptying.
Strength	10 mg/mL Tirzepatide and 10 mg/mL Pyridoxine (B6) sterile injectable solution. Each 3 mL vial contains a total of 30 mg Tirzepatide and 30 mg Pyridoxine.
Route of Administration	Subcutaneous use only (not IV/IM/intranasal/oral)
Side Effects	Nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, dyspepsia
Precautions	Monitor for pancreatitis. Use cautiously in patients with renal impairment or a history of medullary thyroid carcinoma.

Important: Compounded medication dispensed by a 503A pharmacy; not FDA-approved; not listed in the FDA Orange Book; not a therapeutic equivalent or generic of any FDA-approved semaglutide. Identification numbers shown on this page (including NDC and UPC) are supplied by BPI Labs (503B) for listing/inventory purposes only and do not indicate FDA approval, Orange Book listing, or therapeutic equivalence. Not for substitution. Dispensed only pursuant to a valid prescription for an identified individual patient. Not for office use.
Dispensed by: The Pharmacy Hub (503A)

Product Details